# Special Issue

# Resistance to Apoptosis-Based Cancer Therapy—Induction of Non-apoptotic Cell Death to Overcome Chemoresistance

## Message from the Guest Editors

Apoptosis is a form of regulated cell death (RCD) that is essential for organogenesis and tissue homeostasis. Apoptotic stimuli can trigger intrinsic and/or extrinsic cell death pathways. In cancer patients, apoptotic induction by neoadjuvant chemotherapy, biological therapies, and/or radiotherapy can result in cancer cell death. However, cancer cells can swiftly adapt and become refractory to apoptotic therapies, resulting in clinical resistance to apoptosis.

By employing transformative and transdisciplinary approaches to induce non-apoptotic forms of tumor cell death, we may pave the way for the development of novel anticancer therapies with the hope of improving patient longevity.

For this Special Issue, we welcome the submission of original research articles, reviews, mini reviews, case reports, clinical trials, methods, and perspectives that deal with biomarkers/pharmacological/biological/genetic or epigenetic interventions within the broad scope of induction of non-apoptotic cell death to overcome chemoresistance.

## Guest Editors


Dr. Dayanidhi Raman

Dr. Venkataswarup Tiriveedhi

Dr. Anil Shanker

Dr. Amit K. Tiwari


## Deadline for manuscript submissions

closed (31 March 2023)


# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/75658

*Cancers*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)